At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes
20 mai 2024 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2...
Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery
09 mai 2024 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY Medtronic to fund...
Global Prediabetes Treatment Market Analysis & Forecast Report 2024-2034
23 avr. 2024 04h01 HE
|
Research and Markets
Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "Global Prediabetes Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global...
Comprehensive Market Analysis Reveals Significant Insights into the Insulin Pumps and Continuous Glucose Monitors Market Through 2033
03 avr. 2024 12h04 HE
|
Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Insulin Pumps and Continuous Glucose Monitors Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033" report has been added...
Dyadic Reports 2023 Full Year Results and Recent Company Progress
28 mars 2024 16h00 HE
|
Dyadic International, Inc.
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical...
Dyadic Announces Change in Board and Management Leadership Roles
28 mars 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Global Insulin Storage Devices Market to Reach USD 1524.61 Million by 2028 at a CAGR of 8.71%
27 mars 2024 10h42 HE
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global Insulin Storage Devices Market (2023-2028) Competitive Analysis, Impact of Covid-19, Impact of Economic Slowdown & Impending Recession,...
Global Smart Insulin Pens Market Report 2024, Featuring Profiles of Companion Medical, Emperra, Eli Lilly, Bigfoot Biomedical, Diamesco, Pendiq, Medtronic, Diabnext, Diabecare and Capillary Biomedical
25 mars 2024 12h13 HE
|
Research and Markets
Dublin, March 25, 2024 (GLOBE NEWSWIRE) -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.The global smart insulin pens market accounted for USD...
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
11 mars 2024 09h57 HE
|
Dyadic International, Inc.
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The...
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
11 mars 2024 08h30 HE
|
Dyadic International, Inc.
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...